Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Sangamo Therapeutics's operating cash flow for the twelve months ending Mar 31, 2026 was -$90.34M. For fiscal 2025 it was -$97.21M. The highest annual figure on record is $169.88M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$97.21M | – |
| FY2024 | Dec 31, 2024 | -$67.14M | – |
| FY2023 | Dec 31, 2023 | -$224.84M | – |
| FY2022 | Dec 31, 2022 | -$223.63M | – |
| FY2021 | Dec 31, 2021 | -$233.25M | -237.3% |
| FY2020 | Dec 31, 2020 | $169.88M | – |
| FY2019 | Dec 31, 2019 | -$144.40M | -495.1% |
| FY2018 | Dec 31, 2018 | $36.55M | +227.0% |
| FY2017 | Dec 31, 2017 | $11.18M | – |
| FY2016 | Dec 31, 2016 | -$65.88M | – |
| FY2015 | Dec 31, 2015 | -$33.72M | – |
| FY2014 | Dec 31, 2014 | -$5.68M | – |
| FY2013 | Dec 31, 2013 | -$19.48M | – |
| FY2012 | Dec 31, 2012 | -$8.08M | – |
| FY2011 | Dec 31, 2011 | -$25.90M | – |
| FY2010 | Dec 31, 2010 | -$23.93M | – |
| FY2009 | Dec 31, 2009 | -$6.14M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$19.28M | – |
| Q4 FY2025 | Dec 31, 2025 | -$24.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.50M | -342.4% |
| Q2 FY2025 | Jun 30, 2025 | -$18.16M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.15M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.35M | – |
| Q3 FY2024 | Sep 30, 2024 | $11.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.88M | – |
| Q1 FY2024 | Mar 31, 2024 | -$48.66M | – |
| Q4 FY2023 | Dec 31, 2023 | -$50.54M | – |
| Q3 FY2023 | Sep 30, 2023 | -$47.29M | – |
| Q2 FY2023 | Jun 30, 2023 | -$60.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$66.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$57.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$53.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$53.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$58.98M | – |
| Q4 FY2021 | Dec 31, 2021 | -$52.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$59.42M | -279.7% |
| Q2 FY2021 | Jun 30, 2021 | -$52.57M | -132.9% |
| Q1 FY2021 | Mar 31, 2021 | -$68.55M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.30M | – |
| Q3 FY2020 | Sep 30, 2020 | $33.07M | – |
| Q2 FY2020 | Jun 30, 2020 | $159.99M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.89M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.82M | – |
| Q3 FY2019 | Sep 30, 2019 | -$38.87M | – |
| Q2 FY2019 | Jun 30, 2019 | -$39.59M | -132.3% |
| Q1 FY2019 | Mar 31, 2019 | -$45.12M | – |
| Q4 FY2018 | Dec 31, 2018 | -$40.16M | – |
| Q3 FY2018 | Sep 30, 2018 | -$27.60M | – |
| Q2 FY2018 | Jun 30, 2018 | $122.44M | +115.6% |
| Q1 FY2018 | Mar 31, 2018 | -$18.13M | – |
| Q4 FY2017 | Dec 31, 2017 | -$16.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.69M | – |
| Q2 FY2017 | Jun 30, 2017 | $56.79M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.08M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.77M | – |
| Q3 FY2016 | Sep 30, 2016 | -$17.58M | – |
| Q2 FY2016 | Jun 30, 2016 | -$16.18M | – |
See a number that looks wrong?